The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | DTRM-12 with everolimus and pomalidomide in R/R CLL and B-cell lymphomas
Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a phase Ia/Ib study (NCT02900716) exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide (DTRM-555) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) or other B-cell lymphomas. Encouraging clinical activity was observed in several high-risk, multi-refractory CLL and lymphoma patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
